EMA To Restart Landmark Clinical Trial Transparency Policy In September
Executive Summary
The European Medicines Agency is preparing to resume proactively publishing clinical trial data submitted by companies to support their marketing authorization applications for non-COVID-19 products.
You may also be interested in...
EMA To Explain How Trial Transparency & Data Redaction Can Live Together
The European Medicines Agency is working to align the redaction and data anonymization principles underpinning two EU clinical trial transparency initiatives to ensure consistency in disclosure requirements.
EMA Looks For Efficiencies For Companies Ahead Of Relaunching Clinical Data Transparency Policy
Based on its learnings from proactively publishing clinical trial data on COVID-19 products, the European Medicines Agency is making procedural changes to its clinical data publication policy that is set to resume after being temporarily suspended in 2018.
EU Regulators Lift Temporary COVID-19 Measures But Resources Remain An Issue
The European Medicines Agency said that while the temporary measures that were introduced to cope with the peak impact of the COVID-19 pandemic were no longer required, “resourcing within the entire European medicines regulatory network remains a challenge.”